agilon health (AGL) Barclays 28th Annual Global Healthcare Conference summary

Business transformation and financial outlook

• Initiated a major transformation with new contracting, yielding $125M incremental benefit and $500M more expected in 2026.

• Cost trend projected at 7% net for 2026, consistent with prior years, aided by payer benefit design changes shifting costs to members.

• Fourth quarter saw higher-than-expected inpatient claims, including gene therapy, leading to a revised 6.5% cost trend assumption.

• Enhanced quality incentives and reduced Part D exposure to under 15% through contracting.

• Cash position expected to be at least $125M by end of 2026, with a path to free cash flow break-even in 2027.

Data, AI, and clinical pathway initiatives

• Upgraded financial data pipeline and AI algorithms, improving accuracy and visibility of RAF scores and condition-level data.

• Generative AI now parses unstructured data, boosting disease identification and documentation.

• Clinical pathways focus on early disease identification and proactive treatment, with heart failure program live in 90% of markets.

• Heart failure inpatient diagnoses reduced from 25% to under 5%, and readmission rates dropped below 10%.

• COPD and dementia pathways rolling out to 70%+ of markets by end of Q2, using virtual tech and enhanced screening.

Network management and payer relationships

• Aggressively managing physician networks, removing unsustainable panels and focusing on value creation.

• Payer partners receptive to clinical pathway programs, recognizing their impact on quality and outcomes.

• Disciplined approach to contracting, prioritizing positive medical margin and cash flow.

• Portfolio stabilized after significant work; potential for balanced membership growth as economics allow.